477 related articles for article (PubMed ID: 35392964)
1. Cancer combination therapies by angiogenesis inhibitors; a comprehensive review.
Ansari MJ; Bokov D; Markov A; Jalil AT; Shalaby MN; Suksatan W; Chupradit S; Al-Ghamdi HS; Shomali N; Zamani A; Mohammadi A; Dadashpour M
Cell Commun Signal; 2022 Apr; 20(1):49. PubMed ID: 35392964
[TBL] [Abstract][Full Text] [Related]
2. Anti-Angiogenic Therapy: Current Challenges and Future Perspectives.
Lopes-Coelho F; Martins F; Pereira SA; Serpa J
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916438
[TBL] [Abstract][Full Text] [Related]
3. The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF.
Ghalehbandi S; Yuzugulen J; Pranjol MZI; Pourgholami MH
Eur J Pharmacol; 2023 Jun; 949():175586. PubMed ID: 36906141
[TBL] [Abstract][Full Text] [Related]
4. Trends and Challenges in Tumor Anti-Angiogenic Therapies.
Jászai J; Schmidt MHH
Cells; 2019 Sep; 8(9):. PubMed ID: 31540455
[TBL] [Abstract][Full Text] [Related]
5. Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer.
Choi SH; Yoo SS; Lee SY; Park JY
Arch Pharm Res; 2022 Apr; 45(4):263-279. PubMed ID: 35449345
[TBL] [Abstract][Full Text] [Related]
6. Broad targeting of angiogenesis for cancer prevention and therapy.
Wang Z; Dabrosin C; Yin X; Fuster MM; Arreola A; Rathmell WK; Generali D; Nagaraju GP; El-Rayes B; Ribatti D; Chen YC; Honoki K; Fujii H; Georgakilas AG; Nowsheen S; Amedei A; Niccolai E; Amin A; Ashraf SS; Helferich B; Yang X; Guha G; Bhakta D; Ciriolo MR; Aquilano K; Chen S; Halicka D; Mohammed SI; Azmi AS; Bilsland A; Keith WN; Jensen LD
Semin Cancer Biol; 2015 Dec; 35 Suppl(Suppl):S224-S243. PubMed ID: 25600295
[TBL] [Abstract][Full Text] [Related]
7. The impact of tumor receptor heterogeneity on the response to anti-angiogenic cancer treatment.
Li D; Finley SD
Integr Biol (Camb); 2018 Apr; 10(4):253-269. PubMed ID: 29623971
[TBL] [Abstract][Full Text] [Related]
8. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
Leite de Oliveira R; Hamm A; Mazzone M
Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
[TBL] [Abstract][Full Text] [Related]
9. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
10. Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy.
Elebiyo TC; Rotimi D; Evbuomwan IO; Maimako RF; Iyobhebhe M; Ojo OA; Oluba OM; Adeyemi OS
Cancer Treat Res Commun; 2022; 32():100620. PubMed ID: 35964475
[TBL] [Abstract][Full Text] [Related]
11. Novel anti-angiogenic therapies for malignant gliomas.
Norden AD; Drappatz J; Wen PY
Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
[TBL] [Abstract][Full Text] [Related]
12. Angiogenic signaling pathways and anti-angiogenic therapy for cancer.
Liu ZL; Chen HH; Zheng LL; Sun LP; Shi L
Signal Transduct Target Ther; 2023 May; 8(1):198. PubMed ID: 37169756
[TBL] [Abstract][Full Text] [Related]
13. Anti-angiogenic alternatives to VEGF blockade.
Khan KA; Bicknell R
Clin Exp Metastasis; 2016 Feb; 33(2):197-210. PubMed ID: 26620208
[TBL] [Abstract][Full Text] [Related]
14. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoid-mediated effects on angiogenesis in solid tumors.
Martens B; Drebert Z
J Steroid Biochem Mol Biol; 2019 Apr; 188():147-155. PubMed ID: 30654109
[TBL] [Abstract][Full Text] [Related]
16. Tumor angiogenesis and anti-angiogenic therapy.
Kubota Y
Keio J Med; 2012; 61(2):47-56. PubMed ID: 22760023
[TBL] [Abstract][Full Text] [Related]
17. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Ramjiawan RR; Griffioen AW; Duda DG
Angiogenesis; 2017 May; 20(2):185-204. PubMed ID: 28361267
[TBL] [Abstract][Full Text] [Related]
18. Extracellular vimentin mimics VEGF and is a target for anti-angiogenic immunotherapy.
van Beijnum JR; Huijbers EJM; van Loon K; Blanas A; Akbari P; Roos A; Wong TJ; Denisov SS; Hackeng TM; Jimenez CR; Nowak-Sliwinska P; Griffioen AW
Nat Commun; 2022 May; 13(1):2842. PubMed ID: 35606362
[TBL] [Abstract][Full Text] [Related]
19. Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade.
Zheng W; Qian C; Tang Y; Yang C; Zhou Y; Shen P; Chen W; Yu S; Wei Z; Wang A; Lu Y; Zhao Y
Front Immunol; 2022; 13():1035323. PubMed ID: 36439137
[TBL] [Abstract][Full Text] [Related]
20. Metabolic effects of anti-angiogenic therapy in tumors.
Zulato E; Curtarello M; Nardo G; Indraccolo S
Biochimie; 2012 Apr; 94(4):925-31. PubMed ID: 22245704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
